Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1021302810 | 10213028 | 10 | F | 20140514 | 20150922 | 20140603 | 20150930 | EXP | CA-ROCHE-1411736 | ROCHE | 63.12 | YR | F | Y | 0.00000 | 20150930 | N | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1021302810 | 10213028 | 1 | PS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | VIAL | D | S0021A | 103976 | 375 | MG | QOW | |||||
| 1021302810 | 10213028 | 2 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | D | S0021A | 103976 | 375 | MG | |||||||
| 1021302810 | 10213028 | 3 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | D | S0021A | 103976 | |||||||||
| 1021302810 | 10213028 | 4 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | D | S0021A | 103976 | |||||||||
| 1021302810 | 10213028 | 5 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | D | S0021A | 103976 | |||||||||
| 1021302810 | 10213028 | 6 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | D | S0021A | 103976 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 1021302810 | 10213028 | 1 | Asthma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 1021302810 | 10213028 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 1021302810 | 10213028 | Adrenal disorder | |
| 1021302810 | 10213028 | Aspergillus infection | |
| 1021302810 | 10213028 | Asthma | |
| 1021302810 | 10213028 | Bile duct obstruction | |
| 1021302810 | 10213028 | Body temperature decreased | |
| 1021302810 | 10213028 | Drug hypersensitivity | |
| 1021302810 | 10213028 | Psoriasis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 1021302810 | 10213028 | 1 | 20130904 | 0 | ||
| 1021302810 | 10213028 | 2 | 20140514 | 0 | ||
| 1021302810 | 10213028 | 3 | 20140805 | 0 | ||
| 1021302810 | 10213028 | 4 | 20141001 | 0 | ||
| 1021302810 | 10213028 | 5 | 20141029 | 0 | ||
| 1021302810 | 10213028 | 6 | 20141210 | 0 |